Fourth Tommy Hilfiger Fashion Frontier Challenge Calls on Social Entrepreneurs Accelerating Inclusivity in Fashion
Tommy Hilfiger, which is owned by PVH Corp. [NYSE: PVH], is pleased to announce that applications for the fourth edition of the Tommy HilfigerFashion Frontier Challenge areopen. The global program echoes Tommy Hilfiger’s sustainability vision to Waste Nothing and Welcome All, amplifying and supporting new voices in the world of social entrepreneurship who are shaping scalable and disruptive innovations to create a more inclusive future of fashion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220328005210/en/
Tommy Hilfiger Fashion Frontier Challenge 3rd Edition Finale Event (Photo: Business Wire)
In line with Tommy Hilfiger’s commitments towards inclusion, diversity, and acknowledging the gap in equity and equal opportunities, individuals from historically underrepresented communities, including Black, Indigenous, People of Color (BIPOC), people with disabilities and women, are strongly encouraged to apply this year. Applications can be submitted by April 29, 2022, through https://platform.younoodle.com/competition/th_fashion_frontier_challenge_2022.
“The Tommy Hilfiger Fashion Frontier Challenge aims to bring together entrepreneurs from all walks of life, investing knowledge and resources to unlock the unique power of their innovations,” said Tommy Hilfiger. “As an entrepreneur myself, I always wanted to build a global lifestyle brand that is inclusive of everyone — a philosophy that continues to live through this challenge. I truly believe that by coming together we can drive a future of meaningful and long-lasting change.”
The following prizes will be awarded to the winners to support their business idea:
- A total of €200,000 split between two winners
- Additional €15,000 prize for being elected the “Audience’s Favorite Vote”
- A year-long mentorship with Tommy Hilfiger’s internal global experts
- A year-long INSEAD mentorship and course
Tommy Hilfiger is inviting fans of the brand to participate in the first phase of the challenge as Digital Judges. They will help the brand narrow down all applications to the Top 50. Interested applicants are invited to apply until April 20, 2022, through https://platform.younoodle.com/competition/consumer_vote_tommy_hilfiger_fashion_frontier_challenge_2022.
The top 50 applicants will then be narrowed down to six finalists through an internal procedure. Each finalist will be invited to further develop their business plan with the support of dedicated Tommy Hilfiger and external experts ahead of the final event. With training from an experienced pitch coach, each finalist will then present their concept to a jury panel and internal Tommy Hilfiger associate audience at the global Tommy Hilfiger Fashion Frontier Challenge final event in early 2023.
“At Tommy Hilfiger, we want to work together with communities to drive innovation, inclusivity, and diversity to drive long-lasting change,” said Martijn Hagman, CEO, Tommy Hilfiger Global and PVH Europe. “As we kick-off for the fourth Tommy Hilfiger Fashion FrontierChallenge, we really look forward to seeing what ideas come to light that will support communities and help shape the future of fashion.”
Since its inception in 2018, the Tommy Hilfiger Fashion Frontier Challenge has awarded €550,000 to support global entrepreneurs bring their innovative ideas to life, so they can make real changes to their communities. The third edition winners include Lalaland, a Netherlands-based platform that uses artificial intelligence to generate customized and inclusive synthetic models of different ethnicities and UZURI K&Y, a Rwandan-based eco-friendly shoe brand that uses recycled car tires from sub-Saharan Africa and employs local youth. Clothes to Good, a South African-based social enterprise that creates micro-business opportunities and jobs for people with disabilities through textile recycling, was awarded the Audience Favorite vote. More information about Tommy Hilfiger’s sustainability journey, which is powered by PVH’s Forward Fashion strategy can be found on https://global.tommy.com/en_int/about-us-corporate-sustainability.
More information about the Tommy Hilfiger Fashion Frontier Challenge, including how to apply, is available here: https://responsibility.pvh.com/tommy/fashion-frontier-challenge/.
Friends and followers of the brand are invited to join the conversation on social media using #TommyHilfiger, and @TommyHilfiger.
About Tommy Hilfiger
TOMMY HILFIGER is one of the world’s most recognized premium lifestyle brands, uplifting and inspiring consumers since 1985. Colliding the classic with the new to light up what's next, the brand boldly mixes prep style and Americana heritage with fresh perspectives drawn from pop culture to design memorable products and collections. Under Mr. Hilfiger’s vision, TOMMY HILFIGER captures the playful alchemy needed to drive innovative and immersive consumer experiences. At the heart of the brand is the vision to Waste Nothing and Welcome All, an unwavering commitment to sustainability, inclusivity, diversity, and circularity that powers teams to create a better fashion industry.
Global retail sales of TOMMY HILFIGER products were almost $7 billion in 2020. Across the TOMMY HILFIGER and TOMMY JEANS lifestyles, the collections include mens, womens and kids; footwear and accessories; close to body; and a range of license product lines including eyewear, watches and fragrance. Part of PVH Corp., the Tommy Hilfiger Group is powered by more than 16,000 associates worldwide — boasting an extensive distribution network spanning 100 countries and more than 2,000 retail stores, including its largest global flagship store at tommy.com.
About PVH Corp.
PVH is one of the world’s largest and most admired fashion companies, connecting with consumers in over 40 countries. Our global iconic brands include Calvin Klein and TOMMY HILFIGER. Our 140-year history is built on the strength of our brands, our team and our commitment to drive fashion forward for good. That's the Power of Us. That’s the Power of PVH.
Follow us onFacebook, Instagram, Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220328005210/en/
Contact information
Tommy Hilfiger
Virginia Ritchie
Vice President, Global Communications
E-mail: virginia.ritchie@tommy.com
Tel: +31 6 4318 4870
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom